Skip to contentP
Pure Bioscience, Inc.
P
PUREPure Bioscience, Inc. Q1 2022 · 10-Q
Revenue$501.00K$501.00K−68.5% vs Q1 2021 Net Income-$796.00K-$796.00KN/M vs Q1 2021 EPS Diluted-$0.01-$0.01— vs Q1 2021 Gross Profit$329,000−65.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pure Bioscience, Inc. · CIK 1006028 · Engraved from SEC EDGAR
Operating Cash Flow-$576,000N/M Free Cash Flowderived-$630,000N/M Margins · derivedGross margin65.7%+6.0 pt vs Q1 2021
Operating margin-158.7%−147.4 pt vs Q1 2021
Net margin-158.9%−147.6 pt vs Q1 2021
ended Oct 31, 2021 · filed Dec 15, 2021 · 45 d after period end